Seedlabs

Post-Resection ctDNA Surveillance Service for Lung Cancer

A turnkey follow-up program for lung cancer surgery patients that uses serial ctDNA blood tests ('liquid biopsies') to flag molecular signs of residual or recurrent disease after tumor removal.

MedicinePulmonary Hypertension Research and Treatments
Materials Science Information SystemsThoracic oncology — post-surgical lung cancer follow-up and recurrence detection

Concept

A managed surveillance service sold to thoracic surgery and oncology clinics. Every patient enrolled after lung tumor resection is placed on a scheduled series of peripheral blood draws; the service quantifies circulating tumor DNA (ctDNA) at each time point against the pre-surgical baseline and alerts the care team when molecular evidence of residual or recurrent disease appears, alongside routine imaging follow-up. The wedge is strictly post-surgical monitoring of treated lung cancer patients — not screening or initial diagnosis — and it is especially suited to patients whose tumors cannot be easily biopsied.

Why now

[6] demonstrates that ctDNA in peripheral blood carries representative tumor information including gene mutations, that ctDNA can be measured before and after surgical tumor resection in lung cancer patients, and that repeated samples are easily obtained — making serial post-operative monitoring clinically practical and particularly valuable for tumors that are hard to biopsy or remove. [0] indicates thoracic disease management is driven by current, practical diagnostic and treatment information across lung disease and related fields, i.e., a clinical culture receptive to folding practical new diagnostics into routine post-operative pathways.

Written by GLM · 2 Oct 2026

AI assessment

Backed by 2 papers77

A clinically sound application of ctDNA for MRD monitoring, but lacks novelty as it describes a service already offered by the named beneficiaries (Guardant, Natera).

Evidence strength
4/5
The provided research clearly supports the technical feasibility of detecting ctDNA changes post-resection with high specificity.
Market pull
4/5
There is a high clinical urgency for early recurrence detection in lung cancer, and the target beneficiaries are established payers/providers.
Novelty & moat
1/5
The idea is essentially a description of existing commercial products from Guardant Health (Guardant Reveal) and Natera (Signatera), which are explicitly listed as beneficiaries.
Feasibility
5/5
The technology for targeted sequencing of ctDNA is mature and readily available for a small team to implement as a service.
Wedge clarity
5/5
The focus is sharply narrowed to post-surgical surveillance rather than a broad diagnostic platform.
Simplicity / focus
5/5
The product is a single, well-defined service: serial blood tests for a specific patient cohort.

Scored by Gemma 4 · 2 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Nateracompany

    Markets the Signatera ctDNA assay; a structured post-resection surveillance program for thoracic surgery clinics expands test ordering and patient adherence.

  • Guardant Healthcompany

    Liquid biopsy developer; a turnkey lung cancer follow-up workflow grows its minimal residual disease testing volume.

  • Cleveland Clinicorganization

    High-volume thoracic surgery program; a standardized ctDNA follow-up pathway adds structured, earlier recurrence detection to post-operative care.

  • Society of Thoracic Surgeonsorganization

    Maintains a national general thoracic surgery database; a defined post-resection surveillance protocol could become a measurable quality endpoint.

  • GO2 for Lung Cancerorganization

    Advocacy group for lung cancer patients; a simple blood-based follow-up that catches recurrence earlier directly benefits the patients it serves.

Research it builds on

  1. Journal of Thoracic Disease
    Huang, Lin, Kehlet, Henrik, Holbek, Bo Laksafoss et al. · 2026 · 708 citations
    All ideas from this paper →
  2. Circulating tumor DNA detection in lung cancer patients before and after surgery
    Nannan Guo, Feng Lou, Yongfu Ma et al. · 2016 · 122 citations
    All ideas from this paper →
Leave feedback
feasibility